Treatment for Alzheimer’s has long centered on the removal of a certain type of protein in the brain. Unfortunately, an extensive study by the pharmaceutical company, Eli Lilly which focused on developing a drug to remove a protein from the brain known as beta amyloid, did not successfully slow down cognitive decline in patients with early onset of the disease. According to a recent article in The Wall Street Journal (“New Setback in Alzheimer’s Fight”), despite having spent about $1 billion dollars in testing a drug known as solanezumab, Eli Lilly will not seek regulartory approval of the drug.
Eli Lilly and other companies are continuing their research to better understand and treat the role of these protein plaques and declines in cognition. Hopefully, someday soon, new treatment will help alleviate or at least lessen the devastating impact of this horrible disease.